37435-69-1

Usage

Uses

Used in the Food Industry:
5-Hydroxypentanoic Acid Sodium Salt is used as a flavoring agent for its slightly sweet taste, enhancing the flavor profiles of various food products.
Used in Pharmaceutical Applications:
5-Hydroxypentanoic Acid Sodium Salt is used as a pH adjuster and buffer to maintain the stability and effectiveness of pharmaceutical formulations.
Used in Cosmetic Applications:
5-Hydroxypentanoic Acid Sodium Salt is used as a pH adjuster and buffer in cosmetic products to ensure product stability and maintain the desired pH levels for optimal performance.
Used as a Chelating Agent:
5-Hydroxypentanoic Acid Sodium Salt is used as a chelating agent in various applications, including water treatment and industrial processes, to bind and remove metal ions, improving the efficiency and effectiveness of these processes.

Upstream product

• 542-28-9 3,4,5,6-tetrahydro-2H-pyran-2-one 
• 108-29-2 5-methyl-dihydro-furan-2-one 

Downstream Products

• 134848-96-7 benzyl 5-hydroxy pentanoate 
• 64740-39-2 5-benzyloxypentanoic acid 
• 118715-27-8 5-(tert-butyl-diphenyl-silanyloxy)-pentanoic acid 
• 1159408-54-4 5-(((2R,3R,4R,5R,6R)-3-acetamido-4,5-diacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-2-yl)oxy)pentanoic acid 
• 111-29-5 1 ,5-pentanediol 
• 134848-94-5 5-oxo-5-(phenylmethoxy)pentyl (2R,3S)-4-cyclohexyl-2-hydroxy-3-<<(2S)-2-<<(1,1-dimethylethoxy)carbonyl>amino>-3-<<(phenylmethoxy)carbonyl>amino>propanoyl>amino>butanoate 
• 134848-68-3 (3R,4S,7S)-4-(cyclohexylmethyl)-7-<-L-phenylalanyl>amino>-3-hydroxy-2,6,10-trioxo-1-oxa-5,9-diazacyclotetradecane 
• 134848-93-4 5-oxo-5-(phenylmethoxy)pentyl (4S,5R)-4-(cyclohexylmethyl)-2,2-dimethyl-3-<(1,1-dimethylethoxy)carbonyl>-5-oxazolidinecarboxylate 
• 134848-95-6 (3R,4S,7S)-4-(cyclohexylmethyl)-7-<<(1,1-dimethylethoxy)carbonyl>amino>-3-hydroxy-2,6,10-trioxo-1-oxa-5,9-diazacyclotetradecane 
• 216770-56-8 1-O-benzyl-5-O-[1-(4-benzyloxycarbonylbutyl)-2-(3-oxobutyl)]-phosphono-L-erythro-pent-2-ulose ethane-1,2-diyl dithioacetal 
• 216770-60-4 1-O-benzyl-5-O-[1-(4-benzyloxycarbonylbutyl)]-phosphono-L-erythro-pent-2-ulose ethane-1,2-diyl dithioacetal 
• 216770-64-8 1-O-benzyl-5-O-[1-(4-benzyloxycarbonylbutyl)]-phosphono-L-erythro-pent-2-ulose 
• 799294-01-2 3-nitrophenyl 5-benzyloxypentanoate 

Relevant academic research and scientific papers

Mild and chemoselective lactone ring-opening with (TMS)ONa. Mechanistic studies and application to sweroside derivatives

Mild and chemoselective opening of lactones with sodium trimethylsilanolate in high yields and aprotic solvents is described. Kinetic studies demonstrate that the BAc2 mechanistic pathway is followed. Nucleophilic attack of silanolate onto the carbonyl of the lactone moiety is the rate-determining step. NaOH present as an impurity accelerates the reaction. The method was further applied to the base-sensitive and stable lactones derived from highly functionalized iridoid derivatives.

Synthesis of AD-Dihydrodipyrrins Equipped with Latent Substituents of Native Chlorophylls and Bacteriochlorophylls

Native chlorophylls and bacteriochlorophylls share a common trans-substituted pyrroline ring D (17-propionic acid, 18-methyl), whereas diversity occurs in ring A particularly at the 3-position. Two dihydrodipyrrins equipped with native-like D-ring substit

Modified oligonucleotides and compound that can be used for synthesizing same

The present disclosure falls within the field of biomedical technology, and in particular relates to modified oligonucleatides and a compound that can be used for synthesizing same and a method for modifying oligonucleotides. The present disclosure also relates to the use of the modified oligonucleotides for preventing and/or treating diseases associated with the liver in a subject.

POLYNUCLEOTIDE CONSTRUCTS

Disclosed are polynucleotide constructs having a strand linked to a moiety carrying one or more auxiliary moieties. Also disclosed are polynucleotide constructs interrupted with a sugar analogue, and polynucleotide constructs with stereochemical^ enriched phosphorothioates. The polynucleotide constructs may be provided as hybridized polynucleotide constructs. Also featured are methods of delivery a polynucleotide construct to a cell and methods of reducing the expression of a protein in a cell by contacting the cell with the disclosed polynucleotide construct or hybridized polynucleotide construct.

Synthesis of Thymoquinone-Artemisinin Hybrids: New Potent Antileukemia, Antiviral, and Antimalarial Agents

A series of hybrid compounds based on the natural products artemisinin and thymoquinone was synthesized and investigated for their biological activity against the malaria parasite Plasmodium falciparum 3D7 strain, human cytomegalovirus (HCMV), and two leukemia cell lines (drug-sensitive CCRF-CEM and multidrug-resistant subline CEM/ADR5000). An unprecedented one-pot method of selective formation of C-10α-acetate 14 starting from a 1:1 mixture of C-10α- to C-10β-dihydroartemisinin was developed. The key step of this facile method is a mild decarboxylative activation of malonic acid mediated by DCC/DMAP. Ether-linked thymoquinone-artemisinin hybrids 6a/b stood out as the most active compounds in all categories, while showing no toxic side effects toward healthy human foreskin fibroblasts and thus being selective. They exhibited EC50 values of 0.2 μM against the doxorubicin-sensitive as well as the multidrug-resistant leukemia cells and therefore can be regarded as superior to doxorubicin. Moreover, they showed to be five times more active than the standard drug ganciclovir and nearly eight times more active than artesunic acid against HCMV. In addition, hybrids 6a/b possessed excellent antimalarial activity (EC50 = 5.9/3.7 nM), which was better than that of artesunic acid (EC50 = 8.2 nM) and chloroquine (EC50 = 9.8 nM). Overall, most of the presented thymoquinone-artemisinin-based hybrids exhibit an excellent and broad variety of biological activities (anticancer, antimalarial, and antiviral) combined with a low toxicity/high selectivity profile.

Synthesis of Novel Hybrids of Thymoquinone and Artemisinin with High Activity and Selectivity Against Colon Cancer

Colorectal cancer causes 0.5 million deaths each year. To combat this type of cancer the development of new specific drug candidates is urgently needed. In the present work seven novel thymoquinone–artemisinin hybrids with different linkers were synthesized and tested for their in vitro anticancer activity against a panel of various tumor cell lines. The thymoquinone–artesunic acid hybrid 7 a, in which both subunits are connected via an ester bond, was found to be the most active compound and selectively decreased the viability of colorectal cancer cells with an IC50value of 2.4 μm (HCT116) and 2.8 μm (HT29). Remarkably, hybrid 7 a was up to 20-fold more active than its parent compounds (thymoquinone and artesunic acid), while not affecting nonmalignant colon epithelial HCEC cells (IC50>100 μm). Moreover, the activity of hybrid 7 a was superior to that of various 1:1 mixtures of thymoquinone and artesunic acid. Furthermore, hybrid 7 a was even more potent against both colon cancer cell lines than the clinically used drug 5-fluorouracil. These results are another excellent proof of the hybridization concept and confirm that the type and length of the linker play a crucial role for the biological activity of a hybrid drug. Besides an increase in reactive oxygen species (ROS), elevated levels of the DNA-damage marker γ-H2AX were observed. Both effects seem to be involved in the molecular mechanism of action for hybrid 7 a in colorectal cancer cells.

Lipase-mediated regioselective modifications of macrolactonic sophorolipids

Chemoenzymatic synthesis and modification of well-defined macrolactonic sophorolipid (SLML) analogues via a series of successive regioselective de-esterification/transesterification reactions is investigated. Of the lipases screened, Candida antartica lip

POLYNUCLEOTIDE CONSTRUCTS HAVING AN AUXILIARY MOIETY NON-BIOREVERSIBLY LINKED TO AN INTERNUCLEOSIDE PHOSPHATE OR PHOSPHOROTHIOATE

The invention features a hybridized polynucleotide construct including a passenger strand, a guide strand loadable into a RISC complex, and one or more auxiliary moieties. At least one of the auxiliary moieties is non-bioreversibly linked to an internucleoside phosphate or phosphorothioate in the passenger strand. The invention further features methods of delivery a polynucleotide construct to a cell and methods of reducing the expression of a protein in a cell. The methods typically involve contacting the cell with the hybridized polynucleotide construct.

MONONUCLEOTIDES HAVING A BIOREVERSIBLE DISULFIDE GROUP

The invention features a mononucleotide comprising a nucleobase bonded to a sugar having a 3'-carbon and a 5'-carbon, where the 5'-carbon is bonded to a phosphorus (V) atom of a phosphate group through an oxygen atom, the phosphorus (V) atom being bonded to (i) a disulfide bioreversible group through an oxygen atom; and (ii) (a) optionally substituted amino, optionally substituted alkoxy, optionally substituted aryloxy, or optionally substituted heteroaryloxy; or (b) the 3'-carbon through an oxygen atom. The invention also features methods of delivering the mononucleotide to a cell and methods of treating a subject having Hepatitis C.

POLYNUCLEOTIDE CONSTRUCTS HAVING DISULFIDE GROUPS

The invention features polynucleotide constructs containing one or more components (i) containing a disulfide linkage, where each of the one or more components is attached to an internudeotide bridging group or a terminal group of the polynucleotide construct, and each of the one or more components (i) contains one or more bulky groups proximal to the disulfide group. The invention also features polynucleotide constructs containing one or more components (i) containing a disulfide linkage, where each of the one or more components (i) is attached to an internudeotide bridging group or a terminal group of the polynucleotide construct, and each of the one or more components (i) contains at least 4 atoms in a chain between the disulfide linkage and the phosphorus atom of the internudeotide bridging group or the terminal group; and where the chain does not contain a phosphate, an amide, an ester, or an alkenylene. The invention also features methods of delivering a polynucleotide to a cell using the polynucleotide constructs of the invention.